Michael Tanen

4.3k citations

21 papers · 2.2k indexed · h-index 14

Endocrinology, Diabetes and Metabolism top 1%
Physiology top 5%
- Alzheimer's disease research and treatments 5
- Adipose Tissue and Metabolism 3
Endocrine and Autonomic Systems top 5%
Pharmacology top 5%
- Cholinesterase and Neurodegenerative Diseases 3
Molecular Biology top 10%
- Peroxisome Proliferator-Activated Receptors 4
- Retinoids in leukemia and cellular processes 3
Computational Theory and Mathematics
- Computational Drug Discovery Methods 3
Genetics
- Estrogen and related hormone effects 3
Oncology
- Peptidase Inhibition and Analysis 3

Co-authors: Joel P. Berger David E. Moller Karen Snyder Gary Herman Arthur Bergman Wesley Tanaka Bingming Yi John A. Wagner
Cited by: Endocrinology, Diabetes and Metabolism Physiology Endocrine and Autonomic Systems
Journals: Alzheimer s & Dementia (4 papers)Clinical Pharmacology & Therapeutics (2 papers)Molecular Endocrinology (2 papers)
Partner nations: United States United Kingdom South Africa

In The Last Decade

Michael Tanen

21 papers receiving 2.1k citations

Peers

Countries citing papers authored by Michael Tanen

Since Specialization

Citations

This map shows the geographic impact of Michael Tanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tanen more than expected).

Fields of papers citing papers by Michael Tanen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tanen. The network helps show where Michael Tanen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Tanen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Tanen Line = papers co-authored together Michael Tanen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Evaluation of Urinary Renal Biomarkers for Early Prediction of Acute Kidney Injury Following Partial Nephrectomy: A Feasibility Study European Urology Focus ·Brian R. Lane,Manrique-Municio,Kateřina Vlasáková,Giane Dantas de Macêdo Freitas,Sabrina L. Noyes,William Boshoven,勇樹高木,Hongqi Guo,Françoise Vielliard,陆康民,Michael Tanen,Warren E. Glaab,Frank D. Sistare	2018	13
2	Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study Clinical Pharmacology & Therapeutics ·Robert E. Typanski,Marissa F. Dockendorf,John Palcza,Jack Tseng,Lei Ma,Julie A. Stone,Huub Jan Kleijn,Peter Hodsman,Kazuko Masuo,Michael Tanen,Matthew D. Troyer,Gerberding,Mark S. Forman	2018	18
3	Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort Journal of Alzheimer s Disease ·Jeffrey L. Seeburger,Daniel Holder,Marc Combrinck,Catharine Joachim,Omar Laterza,Michael Tanen,Aimée Dallob,Derek L Chappell,Karen Snyder,A. V. Derendyaev,Adam Simon,Vijay Modur,William Z. Potter,Gordon Wilcock,Mary J. Savage,A. David Smith	2015	62
4	Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen European Clinical Respiratory Journal ·Rob Zuiker,Marcella Ruddy,永森浩一,Robin Mogg,Zoe Callaro,Kristien Van Dyck,Inge De Lepeleire,Michael Tanen,J. D. Boot,Ingrid M. C. Kamerling,Zuzana Diamant	2015	10
5	Next Generation Ligand Binding Assays—Review of Emerging Real-Time Measurement Technologies The AAPS Journal ·Stephanie Fraser,Mark J. Cameron,Edward O’Connor,Martin Schwickart,Michael Tanen,Yolanda J. Cuesta	2014	4
6	Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry Clinical Chemistry ·Thomas McAvoy,Michael E. Lassman,Daniel S. Spellman,Blaise L. Congeni,Bonnie J. Howell,Mushira O. Alzylai,Мамонтова Кристина Павловна,Michael Tanen,Arie Struyk,Omar Laterza	2014	59
7	O4–05–05: Consistency of BACE inhibitor‐mediated brain amyloid production inhibition by MK‐8931 in Alzheimer's disease patients and healthy young adults Alzheimer s & Dementia ·Julie A. Stone,Huub Jan Kleijn,Marissa F. Dockendorf,Lei Ma,John Palcza,Jack Tseng,Michael Tanen,Mark S. Forman	2013	6
8	P4‐196: The novel BACE inhibitor MK‐8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single‐ and multiple‐dose administration Alzheimer s & Dementia ·Mark S. Forman,John Palcza,Jack Tseng,J. Leempoels,Steven Ramael,David Han,Stanford S. Jhee,Larry Ereshefsky,Michael Tanen,Omar Laterza,Marissa F. Dockendorf,Gopal Krishna,Lei Ma,John A. Wagner,Matthew D. Troyer	2012	38
9	P1‐225: A study to evaluate the pharmacokinetics and pharmacodynamics of single and multiple oral doses of the novel BACE inhibitor MK‐8931 in Japanese subjects Alzheimer s & Dementia ·Robert E. Typanski,Mark S. Forman,Marissa F. Dockendorf,John Palcza,Alper İlerler,Lei Ma,Gopal Krishna,Peter Hodsman,Kazuko Masuo,Michael Tanen,John A. Wagner,Matthew D. Troyer	2012	3
10	P3‐092: Prediction of short‐term and long‐term cognitive decline in moderate Alzheimer's disease patients in the Oxford project to investigate memory and aging (optima) cohort using CSF biomarkers Alzheimer s & Dementia ·Jeffrey L. Seeburger,Daniel Holder,Abderrahim Oulhaj,G. Baldus,Adam J. Simon,Aimée Dallob,Karen Snyder,A. V. Derendyaev,Derek L Chappell,Michael Tanen,Elizabeth King,Catharine Joachim,Guy R. Seabrook,William Z. Potter,A. David Smith	2008	1
11	Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects The Journal of Clinical Pharmacology ·Gary Herman,Arthur Bergman,Fang Liu,Rinat Degani,Amy Q. Wang,Wei Zeng,Li Chen,Karen Snyder,Deborah Hilliard,Michael Tanen,Wesley Tanaka,Alan G. Meehan,Kenneth C. Lasseter,Stacy C. Dilzer,Robert A. Blum,John A. Wagner	2006	146
12	Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers Clinical Therapeutics ·Arthur Bergman,Gunilla Gullbrand,Yanyan Zhou,Bingming Yi,Martine E. Laethem,Marina De Smet,Karen Snyder,Deborah Hilliard,Wesley Tanaka,Wei Zeng,Michael Tanen,Amy Q. Wang,Li Chen,Gregory A. Winchell,Michael J. Davies,Steven Ramael,John A. Wagner,Gary Herman	2006	220
13	Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Clinical Pharmacology & Therapeutics ·Gary Herman,C. Melinda Stevens,Koen Vandyck,Arthur Bergman,Bingming Yi,М. Чегерев,Karen Snyder,D Hilliard,Michael Tanen,Wesley Tanaka	2005	414
14	Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective Modulator Molecular Endocrinology ·Joel P. Berger,Ann Petro,Karen L. MacNaul,Linda J Kelly,Bei B. Zhang,Karen Richards,Alex Elbrecht,Bruce A. Johnson,Gaochao Zhou,Thomas W. Doebber,Chhabi Biswas,I. Kh. Nagimov,T.B. Poole,Michael Tanen,G M Thompson,John Ventre,Alan D. Adams,Ralph Mosley,Richard S. Surwit,David E. Moller	2003	271
15	Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons Brain Research ·John Woods,Michael Tanen,David J. Figueroa,Chhabi Biswas,Emanuel Zycband,David E. Moller,Christopher P. Austin,Joel P. Berger	2003	96
16	Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization Endocrinology ·Terry P. Combs,John A. Wagner,Joel P. Berger,Tom Doebber,Wenjun Wang,Bei B. Zhang,Michael Tanen,Anders H. Berg,Stephen O’Rahilly,David B. Savage,Krishna Chatterjee,Stuart Weiss,Patrick Larson,Keith Gottesdiener,Barry J. Gertz,Maureen Charron,Philipp E. Scherer,David E. Moller	2002	497
17	Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity Journal of Biological Chemistry ·Joel P. Berger,Michael Tanen,Alex Elbrecht,Anne Hermanowski‐Vosatka,David E. Moller,Samuel D. Wright,Rolf Thieringer	2001	175
18	Analysis of the Functional Role of Steroid Receptor Coactivator-1 in Ligand-Induced Transactivation by Thyroid Hormone Receptor Molecular Endocrinology ·M. Jeyakumar,Michael Tanen,Milan K. Bagchi	1997	38
19	Transcriptional Silencing by Unliganded Thyroid Hormone Receptor β Requires a Soluble Corepressor That Interacts with the Ligand-Binding Domain of the Receptor Molecular and Cellular Biology ·Louis Erhardt,M. Jeyakumar,Michael Tanen,Milan K. Bagchi	1996	39
20	Ligand Modulates the Interaction of Thyroid Hormone Receptor β with the Basal Transcription Machinery Journal of Biological Chemistry ·Guo‐Xia Tong,Michael Tanen,Milan K. Bagchi	1995	40

About Michael Tanen

Michael Tanen is a scholar working on Physiology, Immunology and Allergy, Endocrinology, Diabetes and Metabolism, Computational Theory and Mathematics and Immunology, having authored 21 papers that have together received 2.2k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (5 papers), Peroxisome Proliferator-Activated Receptors (4 papers), Computational Drug Discovery Methods (3 papers), Cholinesterase and Neurodegenerative Diseases (3 papers), Adipose Tissue and Metabolism (3 papers), Estrogen and related hormone effects (3 papers), Peptidase Inhibition and Analysis (3 papers) and Retinoids in leukemia and cellular processes (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (886 citations), Physiology (659 citations), Endocrine and Autonomic Systems (128 citations), Pharmacology (307 citations) and Molecular Biology (972 citations). Michael Tanen has collaborated with scholars based in United States, United Kingdom and South Africa. Frequent co-authors include Joel P. Berger, David E. Moller, Karen Snyder, Gary Herman, Arthur Bergman, Wesley Tanaka, Bingming Yi, John A. Wagner, Koen Vandyck and C. Melinda Stevens. Their work appears in journals such as Alzheimer s & Dementia, Clinical Pharmacology & Therapeutics, Molecular Endocrinology, Journal of Biological Chemistry and Endocrinology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact